# Niagen Bioscience at 18th Annual Southwest IDEAS Conference: growth bets

> Niagen Bioscience presented at the Southwest IDEAS Conference, describing itself as a cash-generating bioscience firm built on nicotinamide riboside. Management cited an FDA reversal on NMN legality and a failed Parkinson's trial as headwinds.

- Date: 2026-11-19 · published 2026-11-20T21:14:25.353Z
- Category: market · region US · magnitude low
- Page: https://feedsoft.ai/events/111128-niagen-bioscience-at-18th-annual-southwest-ideas-conference-growth-bets
- Commodities: [Vitamin B2](https://feedsoft.ai/c/VITB2.md)

## Why it matters

This is a company-specific nutraceutical story with no effect on feed commodity supply or prices.

## Sources

- investing.com: https://www.investing.com/news/transcripts/niagen-bioscience-at-18th-annual-southwest-ideas-conference-growth-bets-93CH-5040272

---
Data from Feedsoft AI (https://feedsoft.ai/). For information only; not investment advice.
